Glaukos Provides Preliminary Fourth Quarter and Full Year 2015 Net Sales and Full Year 2016 Net Sales Guidance
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that it estimates fourth quarter 2015 net sales will be approximately $20.1 million, and its full year 2015 net sales will be approximately $71.5 million, representing approximately 42% and 57% year-over-year growth, respectively.
